Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.19 CAD | +0.33% | +3.61% | +41.38% |
Apr. 02 | Cannabis Stocks Rise Pre-Bell After Florida Supreme Court Allows Ballot Initiative to Legalize Marijuana | MT |
Apr. 02 | Pot producers climb as recreational cannabis to go on Florida ballot | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.38% | 365M | D+ | ||
-15.13% | 4.49B | C+ | ||
-9.75% | 3.06B | B- | ||
+2.14% | 3.04B | C | ||
-6.82% | 2.61B | - | D+ | |
+47.87% | 1.81B | - | ||
+0.09% | 1.66B | - | - | |
-7.89% | 1.63B | - | - | |
-12.97% | 1.55B | C- | ||
+33.40% | 1.41B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACB Stock
- Ratings Aurora Cannabis Inc.